EUR J CANCER:艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验

2017-12-20 MedSci MedSci原创

EUR J CANCER:艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验   紫杉醇联合吉西他滨这种化疗方案用以治疗转移性乳腺癌(MBC)已经获得了很多临床医生的青睐。甲磺酸艾瑞布林是一种微管动力学的非紫杉烷类抑制剂,最新汇总的临床数据显示,甲磺酸艾瑞布林能够提高经蒽环类及紫杉醇治疗过的转移性乳腺癌患者的总生存

 紫杉醇联合吉西他滨这种化疗方案用以治疗转移性乳腺癌(MBC)已经获得了很多临床医生的青睐。甲磺酸艾瑞布林是一种微管动力学的非紫杉烷类抑制剂,最新汇总的临床数据显示,甲磺酸艾瑞布林能够提高经蒽环类及紫杉醇治疗过的转移性乳腺癌患者的总生存期(OS)。

研究者们进行了一项前瞻性、随机、多中心的II期临床研究,用以比较艾瑞布林联合吉西他滨(EG)和紫杉醇联合吉西他滨(PG)作为一线化疗方案的差异。入组病人共计118名,平均年龄50 24-66),EG59名,PG59名,结果显示,6个月无恶化生存期率分别为72%EG)和73%PG),两组在总生存期方面无明显差异,临床受益率分别为44%EG)和49%PG)。

总体来看,艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨两者具有临床效果的相似性,且艾瑞布林联合吉西他滨治疗方案的神经毒性更低。

原始出处:

Park, Yeon Hee, et al. "Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer." European Journal of Cancer 2017 86: 385-393. d oi.org/10.1016/j.ejca

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2089220, encodeId=2e6c20892203a, content=<a href='/topic/show?id=65a2e7058ef' target=_blank style='color:#2F92EE;'>#紫杉醇#</a>联合<a href='/topic/show?id=10dc3890e66' target=_blank style='color:#2F92EE;'>#吉西他滨#</a>这种化疗方案用以治疗<a href='/topic/show?id=324493404ae' target=_blank style='color:#2F92EE;'>#转移性乳腺癌#</a>(MBC)已经获得了很多临床医生的青睐。甲磺酸<a href='/topic/show?id=3881868417f' target=_blank style='color:#2F92EE;'>#艾立布林#</a>是一种微管动力学的<a href='/topic/show?id=7dea104e9955' target=_blank style='color:#2F92EE;'>#非紫杉*类抑制剂#</a>,最新汇总的临床数据显示,甲磺酸艾瑞布林能够提高经<a href='/topic/show?id=a59d88340d2' target=_blank style='color:#2F92EE;'>#蒽环类#</a>及紫杉醇治疗过的转移性<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者的总生存期(OS)。, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77058, encryptionId=65a2e7058ef, topicName=紫杉醇), TopicDto(id=38907, encryptionId=10dc3890e66, topicName=吉西他滨), TopicDto(id=93404, encryptionId=324493404ae, topicName=转移性乳腺癌), TopicDto(id=86841, encryptionId=3881868417f, topicName=艾立布林), TopicDto(id=104799, encryptionId=7dea104e9955, topicName=非紫杉*类抑制剂), TopicDto(id=88340, encryptionId=a59d88340d2, topicName=蒽环类), TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:43:29 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088694, encodeId=5e3a208869493, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Apr 30 06:27:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652808, encodeId=89da165280862, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue May 22 10:27:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924698, encodeId=4437192469846, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19412, encryptionId=74ed1941207, topicName=一线化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Tue Jan 23 17:27:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903945, encodeId=bd2a190394502, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Oct 26 03:27:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931427, encodeId=f6f9193142eb9, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Apr 16 05:27:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386328, encodeId=5fe3138632832, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515457, encodeId=637a151545e1b, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8742, encryptionId=73b18e42ac, topicName=HER2阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2cd10811473, createdName=ms49895894946433513521, createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524634, encodeId=c127152463418, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=)]
    2022-09-20 小小医者

    #紫杉醇#联合#吉西他滨#这种化疗方案用以治疗#转移性乳腺癌#(MBC)已经获得了很多临床医生的青睐。甲磺酸#艾立布林#是一种微管动力学的#非紫杉*类抑制剂#,最新汇总的临床数据显示,甲磺酸艾瑞布林能够提高经#蒽环类#及紫杉醇治疗过的转移性#乳腺癌#患者的总生存期(OS)。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2089220, encodeId=2e6c20892203a, content=<a href='/topic/show?id=65a2e7058ef' target=_blank style='color:#2F92EE;'>#紫杉醇#</a>联合<a href='/topic/show?id=10dc3890e66' target=_blank style='color:#2F92EE;'>#吉西他滨#</a>这种化疗方案用以治疗<a href='/topic/show?id=324493404ae' target=_blank style='color:#2F92EE;'>#转移性乳腺癌#</a>(MBC)已经获得了很多临床医生的青睐。甲磺酸<a href='/topic/show?id=3881868417f' target=_blank style='color:#2F92EE;'>#艾立布林#</a>是一种微管动力学的<a href='/topic/show?id=7dea104e9955' target=_blank style='color:#2F92EE;'>#非紫杉*类抑制剂#</a>,最新汇总的临床数据显示,甲磺酸艾瑞布林能够提高经<a href='/topic/show?id=a59d88340d2' target=_blank style='color:#2F92EE;'>#蒽环类#</a>及紫杉醇治疗过的转移性<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者的总生存期(OS)。, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77058, encryptionId=65a2e7058ef, topicName=紫杉醇), TopicDto(id=38907, encryptionId=10dc3890e66, topicName=吉西他滨), TopicDto(id=93404, encryptionId=324493404ae, topicName=转移性乳腺癌), TopicDto(id=86841, encryptionId=3881868417f, topicName=艾立布林), TopicDto(id=104799, encryptionId=7dea104e9955, topicName=非紫杉*类抑制剂), TopicDto(id=88340, encryptionId=a59d88340d2, topicName=蒽环类), TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:43:29 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088694, encodeId=5e3a208869493, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Apr 30 06:27:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652808, encodeId=89da165280862, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue May 22 10:27:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924698, encodeId=4437192469846, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19412, encryptionId=74ed1941207, topicName=一线化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Tue Jan 23 17:27:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903945, encodeId=bd2a190394502, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Oct 26 03:27:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931427, encodeId=f6f9193142eb9, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Apr 16 05:27:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386328, encodeId=5fe3138632832, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515457, encodeId=637a151545e1b, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8742, encryptionId=73b18e42ac, topicName=HER2阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2cd10811473, createdName=ms49895894946433513521, createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524634, encodeId=c127152463418, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2089220, encodeId=2e6c20892203a, content=<a href='/topic/show?id=65a2e7058ef' target=_blank style='color:#2F92EE;'>#紫杉醇#</a>联合<a href='/topic/show?id=10dc3890e66' target=_blank style='color:#2F92EE;'>#吉西他滨#</a>这种化疗方案用以治疗<a href='/topic/show?id=324493404ae' target=_blank style='color:#2F92EE;'>#转移性乳腺癌#</a>(MBC)已经获得了很多临床医生的青睐。甲磺酸<a href='/topic/show?id=3881868417f' target=_blank style='color:#2F92EE;'>#艾立布林#</a>是一种微管动力学的<a href='/topic/show?id=7dea104e9955' target=_blank style='color:#2F92EE;'>#非紫杉*类抑制剂#</a>,最新汇总的临床数据显示,甲磺酸艾瑞布林能够提高经<a href='/topic/show?id=a59d88340d2' target=_blank style='color:#2F92EE;'>#蒽环类#</a>及紫杉醇治疗过的转移性<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者的总生存期(OS)。, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77058, encryptionId=65a2e7058ef, topicName=紫杉醇), TopicDto(id=38907, encryptionId=10dc3890e66, topicName=吉西他滨), TopicDto(id=93404, encryptionId=324493404ae, topicName=转移性乳腺癌), TopicDto(id=86841, encryptionId=3881868417f, topicName=艾立布林), TopicDto(id=104799, encryptionId=7dea104e9955, topicName=非紫杉*类抑制剂), TopicDto(id=88340, encryptionId=a59d88340d2, topicName=蒽环类), TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:43:29 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088694, encodeId=5e3a208869493, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Apr 30 06:27:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652808, encodeId=89da165280862, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue May 22 10:27:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924698, encodeId=4437192469846, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19412, encryptionId=74ed1941207, topicName=一线化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Tue Jan 23 17:27:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903945, encodeId=bd2a190394502, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Oct 26 03:27:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931427, encodeId=f6f9193142eb9, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Apr 16 05:27:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386328, encodeId=5fe3138632832, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515457, encodeId=637a151545e1b, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8742, encryptionId=73b18e42ac, topicName=HER2阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2cd10811473, createdName=ms49895894946433513521, createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524634, encodeId=c127152463418, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2089220, encodeId=2e6c20892203a, content=<a href='/topic/show?id=65a2e7058ef' target=_blank style='color:#2F92EE;'>#紫杉醇#</a>联合<a href='/topic/show?id=10dc3890e66' target=_blank style='color:#2F92EE;'>#吉西他滨#</a>这种化疗方案用以治疗<a href='/topic/show?id=324493404ae' target=_blank style='color:#2F92EE;'>#转移性乳腺癌#</a>(MBC)已经获得了很多临床医生的青睐。甲磺酸<a href='/topic/show?id=3881868417f' target=_blank style='color:#2F92EE;'>#艾立布林#</a>是一种微管动力学的<a href='/topic/show?id=7dea104e9955' target=_blank style='color:#2F92EE;'>#非紫杉*类抑制剂#</a>,最新汇总的临床数据显示,甲磺酸艾瑞布林能够提高经<a href='/topic/show?id=a59d88340d2' target=_blank style='color:#2F92EE;'>#蒽环类#</a>及紫杉醇治疗过的转移性<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者的总生存期(OS)。, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77058, encryptionId=65a2e7058ef, topicName=紫杉醇), TopicDto(id=38907, encryptionId=10dc3890e66, topicName=吉西他滨), TopicDto(id=93404, encryptionId=324493404ae, topicName=转移性乳腺癌), TopicDto(id=86841, encryptionId=3881868417f, topicName=艾立布林), TopicDto(id=104799, encryptionId=7dea104e9955, topicName=非紫杉*类抑制剂), TopicDto(id=88340, encryptionId=a59d88340d2, topicName=蒽环类), TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:43:29 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088694, encodeId=5e3a208869493, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Apr 30 06:27:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652808, encodeId=89da165280862, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue May 22 10:27:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924698, encodeId=4437192469846, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19412, encryptionId=74ed1941207, topicName=一线化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Tue Jan 23 17:27:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903945, encodeId=bd2a190394502, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Oct 26 03:27:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931427, encodeId=f6f9193142eb9, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Apr 16 05:27:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386328, encodeId=5fe3138632832, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515457, encodeId=637a151545e1b, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8742, encryptionId=73b18e42ac, topicName=HER2阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2cd10811473, createdName=ms49895894946433513521, createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524634, encodeId=c127152463418, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2089220, encodeId=2e6c20892203a, content=<a href='/topic/show?id=65a2e7058ef' target=_blank style='color:#2F92EE;'>#紫杉醇#</a>联合<a href='/topic/show?id=10dc3890e66' target=_blank style='color:#2F92EE;'>#吉西他滨#</a>这种化疗方案用以治疗<a href='/topic/show?id=324493404ae' target=_blank style='color:#2F92EE;'>#转移性乳腺癌#</a>(MBC)已经获得了很多临床医生的青睐。甲磺酸<a href='/topic/show?id=3881868417f' target=_blank style='color:#2F92EE;'>#艾立布林#</a>是一种微管动力学的<a href='/topic/show?id=7dea104e9955' target=_blank style='color:#2F92EE;'>#非紫杉*类抑制剂#</a>,最新汇总的临床数据显示,甲磺酸艾瑞布林能够提高经<a href='/topic/show?id=a59d88340d2' target=_blank style='color:#2F92EE;'>#蒽环类#</a>及紫杉醇治疗过的转移性<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者的总生存期(OS)。, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77058, encryptionId=65a2e7058ef, topicName=紫杉醇), TopicDto(id=38907, encryptionId=10dc3890e66, topicName=吉西他滨), TopicDto(id=93404, encryptionId=324493404ae, topicName=转移性乳腺癌), TopicDto(id=86841, encryptionId=3881868417f, topicName=艾立布林), TopicDto(id=104799, encryptionId=7dea104e9955, topicName=非紫杉*类抑制剂), TopicDto(id=88340, encryptionId=a59d88340d2, topicName=蒽环类), TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:43:29 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088694, encodeId=5e3a208869493, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Apr 30 06:27:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652808, encodeId=89da165280862, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue May 22 10:27:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924698, encodeId=4437192469846, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19412, encryptionId=74ed1941207, topicName=一线化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Tue Jan 23 17:27:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903945, encodeId=bd2a190394502, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Oct 26 03:27:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931427, encodeId=f6f9193142eb9, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Apr 16 05:27:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386328, encodeId=5fe3138632832, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515457, encodeId=637a151545e1b, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8742, encryptionId=73b18e42ac, topicName=HER2阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2cd10811473, createdName=ms49895894946433513521, createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524634, encodeId=c127152463418, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2089220, encodeId=2e6c20892203a, content=<a href='/topic/show?id=65a2e7058ef' target=_blank style='color:#2F92EE;'>#紫杉醇#</a>联合<a href='/topic/show?id=10dc3890e66' target=_blank style='color:#2F92EE;'>#吉西他滨#</a>这种化疗方案用以治疗<a href='/topic/show?id=324493404ae' target=_blank style='color:#2F92EE;'>#转移性乳腺癌#</a>(MBC)已经获得了很多临床医生的青睐。甲磺酸<a href='/topic/show?id=3881868417f' target=_blank style='color:#2F92EE;'>#艾立布林#</a>是一种微管动力学的<a href='/topic/show?id=7dea104e9955' target=_blank style='color:#2F92EE;'>#非紫杉*类抑制剂#</a>,最新汇总的临床数据显示,甲磺酸艾瑞布林能够提高经<a href='/topic/show?id=a59d88340d2' target=_blank style='color:#2F92EE;'>#蒽环类#</a>及紫杉醇治疗过的转移性<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者的总生存期(OS)。, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77058, encryptionId=65a2e7058ef, topicName=紫杉醇), TopicDto(id=38907, encryptionId=10dc3890e66, topicName=吉西他滨), TopicDto(id=93404, encryptionId=324493404ae, topicName=转移性乳腺癌), TopicDto(id=86841, encryptionId=3881868417f, topicName=艾立布林), TopicDto(id=104799, encryptionId=7dea104e9955, topicName=非紫杉*类抑制剂), TopicDto(id=88340, encryptionId=a59d88340d2, topicName=蒽环类), TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:43:29 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088694, encodeId=5e3a208869493, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Apr 30 06:27:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652808, encodeId=89da165280862, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue May 22 10:27:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924698, encodeId=4437192469846, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19412, encryptionId=74ed1941207, topicName=一线化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Tue Jan 23 17:27:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903945, encodeId=bd2a190394502, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Oct 26 03:27:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931427, encodeId=f6f9193142eb9, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Apr 16 05:27:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386328, encodeId=5fe3138632832, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515457, encodeId=637a151545e1b, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8742, encryptionId=73b18e42ac, topicName=HER2阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2cd10811473, createdName=ms49895894946433513521, createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524634, encodeId=c127152463418, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2089220, encodeId=2e6c20892203a, content=<a href='/topic/show?id=65a2e7058ef' target=_blank style='color:#2F92EE;'>#紫杉醇#</a>联合<a href='/topic/show?id=10dc3890e66' target=_blank style='color:#2F92EE;'>#吉西他滨#</a>这种化疗方案用以治疗<a href='/topic/show?id=324493404ae' target=_blank style='color:#2F92EE;'>#转移性乳腺癌#</a>(MBC)已经获得了很多临床医生的青睐。甲磺酸<a href='/topic/show?id=3881868417f' target=_blank style='color:#2F92EE;'>#艾立布林#</a>是一种微管动力学的<a href='/topic/show?id=7dea104e9955' target=_blank style='color:#2F92EE;'>#非紫杉*类抑制剂#</a>,最新汇总的临床数据显示,甲磺酸艾瑞布林能够提高经<a href='/topic/show?id=a59d88340d2' target=_blank style='color:#2F92EE;'>#蒽环类#</a>及紫杉醇治疗过的转移性<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者的总生存期(OS)。, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77058, encryptionId=65a2e7058ef, topicName=紫杉醇), TopicDto(id=38907, encryptionId=10dc3890e66, topicName=吉西他滨), TopicDto(id=93404, encryptionId=324493404ae, topicName=转移性乳腺癌), TopicDto(id=86841, encryptionId=3881868417f, topicName=艾立布林), TopicDto(id=104799, encryptionId=7dea104e9955, topicName=非紫杉*类抑制剂), TopicDto(id=88340, encryptionId=a59d88340d2, topicName=蒽环类), TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:43:29 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088694, encodeId=5e3a208869493, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Apr 30 06:27:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652808, encodeId=89da165280862, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue May 22 10:27:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924698, encodeId=4437192469846, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19412, encryptionId=74ed1941207, topicName=一线化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Tue Jan 23 17:27:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903945, encodeId=bd2a190394502, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Oct 26 03:27:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931427, encodeId=f6f9193142eb9, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Apr 16 05:27:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386328, encodeId=5fe3138632832, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515457, encodeId=637a151545e1b, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8742, encryptionId=73b18e42ac, topicName=HER2阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2cd10811473, createdName=ms49895894946433513521, createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524634, encodeId=c127152463418, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2089220, encodeId=2e6c20892203a, content=<a href='/topic/show?id=65a2e7058ef' target=_blank style='color:#2F92EE;'>#紫杉醇#</a>联合<a href='/topic/show?id=10dc3890e66' target=_blank style='color:#2F92EE;'>#吉西他滨#</a>这种化疗方案用以治疗<a href='/topic/show?id=324493404ae' target=_blank style='color:#2F92EE;'>#转移性乳腺癌#</a>(MBC)已经获得了很多临床医生的青睐。甲磺酸<a href='/topic/show?id=3881868417f' target=_blank style='color:#2F92EE;'>#艾立布林#</a>是一种微管动力学的<a href='/topic/show?id=7dea104e9955' target=_blank style='color:#2F92EE;'>#非紫杉*类抑制剂#</a>,最新汇总的临床数据显示,甲磺酸艾瑞布林能够提高经<a href='/topic/show?id=a59d88340d2' target=_blank style='color:#2F92EE;'>#蒽环类#</a>及紫杉醇治疗过的转移性<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者的总生存期(OS)。, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77058, encryptionId=65a2e7058ef, topicName=紫杉醇), TopicDto(id=38907, encryptionId=10dc3890e66, topicName=吉西他滨), TopicDto(id=93404, encryptionId=324493404ae, topicName=转移性乳腺癌), TopicDto(id=86841, encryptionId=3881868417f, topicName=艾立布林), TopicDto(id=104799, encryptionId=7dea104e9955, topicName=非紫杉*类抑制剂), TopicDto(id=88340, encryptionId=a59d88340d2, topicName=蒽环类), TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:43:29 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088694, encodeId=5e3a208869493, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Apr 30 06:27:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652808, encodeId=89da165280862, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue May 22 10:27:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924698, encodeId=4437192469846, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19412, encryptionId=74ed1941207, topicName=一线化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Tue Jan 23 17:27:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903945, encodeId=bd2a190394502, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Oct 26 03:27:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931427, encodeId=f6f9193142eb9, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Apr 16 05:27:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386328, encodeId=5fe3138632832, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515457, encodeId=637a151545e1b, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8742, encryptionId=73b18e42ac, topicName=HER2阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2cd10811473, createdName=ms49895894946433513521, createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524634, encodeId=c127152463418, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2089220, encodeId=2e6c20892203a, content=<a href='/topic/show?id=65a2e7058ef' target=_blank style='color:#2F92EE;'>#紫杉醇#</a>联合<a href='/topic/show?id=10dc3890e66' target=_blank style='color:#2F92EE;'>#吉西他滨#</a>这种化疗方案用以治疗<a href='/topic/show?id=324493404ae' target=_blank style='color:#2F92EE;'>#转移性乳腺癌#</a>(MBC)已经获得了很多临床医生的青睐。甲磺酸<a href='/topic/show?id=3881868417f' target=_blank style='color:#2F92EE;'>#艾立布林#</a>是一种微管动力学的<a href='/topic/show?id=7dea104e9955' target=_blank style='color:#2F92EE;'>#非紫杉*类抑制剂#</a>,最新汇总的临床数据显示,甲磺酸艾瑞布林能够提高经<a href='/topic/show?id=a59d88340d2' target=_blank style='color:#2F92EE;'>#蒽环类#</a>及紫杉醇治疗过的转移性<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者的总生存期(OS)。, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77058, encryptionId=65a2e7058ef, topicName=紫杉醇), TopicDto(id=38907, encryptionId=10dc3890e66, topicName=吉西他滨), TopicDto(id=93404, encryptionId=324493404ae, topicName=转移性乳腺癌), TopicDto(id=86841, encryptionId=3881868417f, topicName=艾立布林), TopicDto(id=104799, encryptionId=7dea104e9955, topicName=非紫杉*类抑制剂), TopicDto(id=88340, encryptionId=a59d88340d2, topicName=蒽环类), TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Tue Sep 20 04:43:29 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088694, encodeId=5e3a208869493, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Mon Apr 30 06:27:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652808, encodeId=89da165280862, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue May 22 10:27:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924698, encodeId=4437192469846, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19412, encryptionId=74ed1941207, topicName=一线化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Tue Jan 23 17:27:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903945, encodeId=bd2a190394502, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Oct 26 03:27:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931427, encodeId=f6f9193142eb9, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Apr 16 05:27:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386328, encodeId=5fe3138632832, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515457, encodeId=637a151545e1b, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8742, encryptionId=73b18e42ac, topicName=HER2阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2cd10811473, createdName=ms49895894946433513521, createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524634, encodeId=c127152463418, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Dec 22 10:27:00 CST 2017, time=2017-12-22, status=1, ipAttribution=)]

相关资讯

卫材公布新型抗癌药Halaven治疗软组织肉瘤III期临床新数据

日本药企卫材(Eisai)近日在日本神户举行的第14届日本肿瘤内科学年会(JSMO)上公布了新型抗癌药Halaven(eribulin mesylate,甲磺酸艾瑞布林)一项III期临床研究(Study 309)的额外分析数据。 该研究是一项多中心、开放标签、随机III期研究,在452例(年龄18岁及以上)经标准疗法(包括蒽环类及至少一种其他化疗方案)治疗后病情进展的局部晚期、复发性或转移性软组

Future Oncol:艾瑞布林治疗乳腺癌眼转移安全有效

  Future Oncol:艾瑞布林治疗乳腺癌眼转移安全有效 约40%早期乳腺癌将会发展为转移性乳腺癌(MBC),肺、肝、骨、脑是常见转移部位,脉络膜转移却是很罕见的转移部位,尽管以蒽环和紫衫的方案作为MBC治疗的基石并且取得了很好的疗效,但难治性MBC的治疗目前没有标准方案。 甲磺酸艾瑞布林是人工合成的软海绵素类似物,旨在抑制微管活动,目前的III期研究正评价其效果和耐受